The GC patients were divided into four groups, namely, TP53-/PIK3CA-, TP53-/PIK3CA+, TP53+/PIK3CA-, and TP53+/PIK3CA+, and Kaplan-Meier analyses were conducted to estimate the prognostic impact of TP53 and PIK3CA mutations. This evidence concerns the gene PIK3CA and gastric cancer.